Vandana Nehra, M.D.

Closed for Enrollment

• A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

  To determine the effects of 12 weeks administration of different dose levels of ALV003 on the mucosal lining of the small intestine and symptoms in celiac disease patients.

• Understanding Predictors of Success in a Comprehensive Lifestyle Treatment Program for Obesity: The Fecal Microbiome. Rochester, Minn.

  The purpose of this study is to find out how the naturally occurring bacteria (the microbiome) in your gut can affect your body weight